The difficulty of policymaking with a divided government and electorate was the underlying theme of the Research into Policy and Practice webinar sponsored by the Department of Health Policy at Vanderbilt University Medical Center as panelists and attendees gathered virtually to take measure of the post-election American landscape, over which hangs the pall of a surging pandemic.

Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.

After a sharp drop in out-of-pocket costs between 2010 and 2011, Medicare patients who use specialty biologic medications for rheumatoid arthritis have seen higher out-of-pocket spending for those same drugs because of gradual price increases, a new study finds.

Medicare Part D enrollees may pay more out of pocket for high-priced specialty generic drugs than their brand-name counterparts, according to new research by health policy experts at Vanderbilt University Medical Center and the University of North Carolina at Chapel Hill.

As both drug prices and out-of-pocket expense for prescription medications continue to climb, a team of Health Policy experts at Vanderbilt University School of Medicine (VUSM) have received a grant to determine if these factors are causing older Americans enrolled in Medicare Part D for medication coverage to delay or never fill their prescriptions.

Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.